File No. SND/MA/23/000154
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(Subsequent New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated: 24 NOV 2023

To

M/s. Precise Biopharma Pvt. Ltd.,
E 311, E 312, Eastern Business District, LBS Road,
Bhandup (W), Mumbai, Maharashtra (India)-400078.

Subject: **Permission to conduct Phase III Clinical trial of Tofacitinib Lotion 2% w/v - A Multicentric, Randomized, Open Label, Active Controlled, two arm, Parallel Group, Comparative, Prospective, Phase III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Tofacitinib Lotion 2% w/v Versus Pimecrolimus cream 1% w/w for the Treatment of Patients with Mild to Moderate Atopic Dermatitis". (Protocol No. CT/2023/35, Version No.: 00, Date: 15.05.2023) - Reg.**

CT NOC No.: **CT/SND/26/2023**

Sir,

With reference to your Application No. SND/CT21/FF/2023/37727 dated 01-Jun-2023 please find enclosed herewith the permission in Form CT-06, CT NOC No. **CT/SND/26/2023** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

Yours faithfully,

(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority

Conditions of Permission

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

(ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;

(xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt

of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xv) The Laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

(xix) It may kindly be noted that merely granting permission to conduct Clinical trial with the drug does not convey or imply that based on the Clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG ~~OR INVESTIGATIONAL NEW DRUG~~

CT NOC NO.: CT/SND/26/2023

The Central Licensing Authority hereby permits **M/s Precise Biopharma Pvt. Ltd., E 311, E 312, Eastern Business District, LBS Road, Bhandup (W), Mumbai, Maharashtra (India)-400078** to conduct clinical trial of the new drug ~~or investigational new drug~~ as per **Protocol No. CT/2023/35, Version No.: 00, Date: 15.05.2023** in the below mentioned clinical trial sites.

2. Details of new drug or ~~investigational new drug~~:

Names of the new drug:	Tofacitinib Lotion 2% w/v
Therapeutic class:	Janus kinase JAK inhibitors
Dosage form:	Lotion
Composition:	Each gram contains: Tofacitinib citrate equivalent to Tofacitinib..... 2% w/v
Indications:	For the treatment of Atopic Dermatitis.

Details of clinical trial sites

Sr. No.	Name of Principal Investigator & Trial sites	Ethics Committee Name/ Registration Number
1	Dr. Bindiya Bansal, Maharaja Agrasen Superspeciality Hospital, Central Spine, Agrasen Aspatal Marg, Sector 7, Vidyadhar Nagar, Jaipur-302039, Rajasthan.	Institutional Ethics Committee, Maharaja Agrasen Superspeciality Hospital, Central Spine, Agrasen Aspatal Marg, Sector 7, Vidyadhar Nagar, Jaipur-302039, Rajasthan. Reg. No. ECR/1222/Inst/RJ/2019/RR-22
2	Dr. Raj Kumar Kothiwala, Department of Dermatology, Venereology and Leprosy, Jawahar Lal Nehru (J.L.N) Medical College, Kala Bagh, Ajmer-305001, Rajasthan.	Institutional Ethics Committee, Jawahar Lal Nehru Medical College, Kala Bagh, Ajmer-305001, Rajasthan. ECR/1156/Inst/RJ/2018/RR-22
3	Dr. Dev Prakash Shivhare, Department of Dermatology, LLR Hospital, GSVM Medical College, Swaroop Nagar, Kanpur-208002, Uttar Pradesh.	Ethics Committee, GSVM Medical College, Room No-125, 1st Floor, Swaroop Nagar, Kanpur-208002, Uttar Pradesh. ECR/680/Inst/UP/2014/RR-20
4	Dr. Raja Bhattacharya, Department of Medicine, Medical College and Hospital, Kolkata, MCH Building, 4th Floor, 88 College Street, Kolkata-700073, West Bengal.	Institutional Ethics Committee for Human Research, Medical College and Hospital, Kolkata, 88, College Street, Kolkata-700073, West Bengal. ECR/287/Inst/WB/2013/RR-19
5	Dr. Jayanta Kumar Barua, Department of Dermatology, Calcutta School of Tropical Medicine, Government of West Bengal, 108, Chittranjan Avenue, Calcutta-700073, West Bengal.	Clinical Research Ethics Committee, Department of Clinical and Experimental Pharmacology, Calcutta School of Tropical Medicine, 108, C R Avenue, Kolkata-700073, West Bengal ECR/194/Inst/WB/2013/RR-20

6	Dr. Indrashis Podder, Department of Dermatology, Venereology and Leprosy, College of Medicine & Sagore Dutta Hospital, 578, B.T. Road, Kamarhati, Kolkata-700058, West Bengal.	Institutional Ethics Committee, College of Medicine & Sagore Dutta Hospital, Office of Principal, 578, B.T. Road, Kamarhati, Kolkata-700058, West Bengal. ECR/1210/Inst/WB/2019/RR-22
7	Dr. Avdhut Bhalchandra Deshpande, Prakash Institute of Medical Sciences & Research (PIMS&R), Urun-Islampur, Islampur-Sangali Road, Islampur, Tal-Walwa, Dist-Sangali-415409, Maharashtra	Prakash Medical College Institutional Ethics Committee, Prakash Institute of Medical Sciences & Research (PIMS&R), Urun-Islampur, Islampur-Sangali Road, Islampur, Tal-Walwa, Dist-Sangali-415409, Maharashtra. ECR/1052/Inst/MH/2018/RR-21
8	Dr. Sunil Kumar Prabhu B, Redkar Hospital and Research Centre, Mumbai-Goa Highway, Oxelbag, Dhargal, Tal-Pernem, Goa-403513.	Redkar Hospital Institutional Ethics Committee (RHIEC), Redkar Hospital and Research Centre, Mumbai-Goa Highway, Oxelbag, Dhargal, Pernem, Goa-403513. ECR/902/Inst/GA/2018/RR-21
9	Dr. Gamit Hemangini Harishbhai, Hope Well Medical Hospital, Block G, 1st Floor, 101, 102, Sumel-8, Nr. Ajit Mill Char Rasta, Rakhiyal, Ahmedabad-380023, Gujarat.	Sangini Hospital Ethics Committee C/o Sangini Hospital, First Floor, Santorini Square, B/H Abhishree Complex, Opp. Star Bazar Lane, Nr. Jodhpur Cross Roads, Satellite, Ahmedabad-380015, Gujarat. ECR/147/Inst/GJ/2013/RR-19
10	Dr. Patnala Guru Prasad, Department of Dermatology, King George Hospital, Andhra Medical College, Maharanipeta, Visakhapatnam-530002, Andhra Pradesh.	Institutional Ethics Committee, King George Hospital, Maharanipeta, Collector Office Junction, Visakhapatnam-530002, Andhra Pradesh. ECR/197/Inst/KGH/2013/RR-20
11	Dr. Gurram Narasimha Rao Netha, Department of Dermatology, Venereology and Leprosy, 5 th Floor, Gandhi Hospital, Musheerabad, Secunderabad-500003, Telangana.	Institutional Ethics Committee, Gandhi Medical College/Gandhi Hospital, Musheerabad, Secunderabad-500003, Telangana. ECR/180/Inst/AP/2013/RR-19

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority
Stamp

Place: New Delhi
Date:
24 NOV 2023

Dr. Rajeev Singh Raghuvanshi
Drugs Controller General (India)
Central Drugs Standard Control Organisation
Directorate General of Health Services
Ministry of Health & Family Welfare
Government of India
FDA Bhawan, Kotla Road,
New Delhi (India)